SCHEMBL5136226

SCHEMBL5136226

CCCCN(CCCC)c1ccc(CN(Cc2c(-c3ccccc3)nc(-c3ccccc3)n2CCCC)CC2CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
BCHE P06276 3/20 0.36
TSHR P16473 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 3/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.36
ABCC1 P33527 1/20 0.35
HDAC1 Q13547 1/20 0.34
ALOX15 P16050 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
CRHR1 P34998 1/20 0.33
RORC P51449 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764006 0.91 ABCC1 (0.43) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5135713 0.91 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137864 0.91 C5AR1 (0.44) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5134999 0.90 C5AR1 (0.44) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5134910 0.90 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134718 0.89 C5AR1 (0.43) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5137114 0.89 C5AR1 (0.43) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL5135753 0.89 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135678 0.89 C5AR1 (0.43) C5AR1BCHETSHRKDM4EALDH1A1
SCHEMBL648237 0.88 TSHR (0.42) C5AR1BCHETSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed